Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma

NCT ID: NCT06705335

Last Updated: 2025-10-02

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2026-01-31
• Study Completion Date: 2029-01-31

Brief Summary

This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.

Detailed Description

After checking the inclusion criteria and signing the consent form, patients will be pre-selected for the study.

A tumour sample (primary tumour or metastasis) will be taken either during a biopsy or during pancreatic or metastasis surgery.

A blood sample will be taken on the same day as the tumour sample. The inclusion visit will be carried out by the investigating physician and will correspond to the visit when the results of the biopsy or surgery are reported.

Inclusion of the patient will be possible if the tumour sample has been taken, is available, contributory and malignant (diagnosis or confirmation of pancreatic adenocarcinoma) and if the blood sample has been taken and is available.

The patient will be considered to have failed pre-selection if

• the tumour sample has not been taken or is not available, or
• the tumour sample/histological result is non-contributory, or
• the histological result is benign, or
• the blood sample was not taken or is not available, or
• the patient refuses to continue the study, or
• the patient has withdrawn consent, or
• any other reason preventing inclusion of the patient. Included patients will be treated and followed as usual, with standard radiological follow-up.

For two years after inclusion, the tumour status (first progression) and vital status of the patient (alive, dead or lost to follow-up at the date of the visit) will be collected.

Conditions

Pancreas Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

CONVERCAP patients

The tumour sample (primary tumour or metastasis) will be taken either during a standard biopsy or during pancreatic or metastasis standard surgery.

Biopsy sampling of metastases is only authorised if the primary histological diagnosis of pancreatic adenocarcinoma has already been proven. If the patient has undergone a biopsy for diagnostic purposes, he/she cannot be included in the study.

The blood sample will be taken on the same day as the tumour sample.

Blood sample

Intervention Type: OTHER

On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.

Interventions

Blood sample

On the same day as the tumour sample is taken (biopsy or surgery), a blood sample of approximately 15 to 20 mL is taken in EDTA-free tubes.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 18 years.

2. Pancreatic adenocarcinoma (suspected on radiological assessment or histologically proven):

1. Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer.

2. Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer.

3. Whatever the stage of the disease.

4. Whatever the type of treatment proposed (systemic, surgery, radiotherapy, etc.).

5. Patient who has never received systemic treatment or advanced radiotherapy.

6. WHO 0-1-2.

7. Life expectancy > 3 months.

8. Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).

9. Patient affiliated to a social security scheme in compliance with Article 1121-11 of the French Public Health Code.

Exclusion Criteria

1. Indication for biopsy for primary diagnosis of pancreatic cancer

2. No indication for treatment of pancreatic cancer.

3. Adjuvant/neoadjuvant chemotherapy completed less than 6 months ago in the case of patients with recurrent disease.

4. Patient already included in the study.

5. Geographical, social or psychological factors rendering the patient unable to undergo study monitoring and procedures.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Institut Bergonié

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Simon PERNOT, Dr

Role: PRINCIPAL_INVESTIGATOR

Institut Bergonié

Central Contacts

Simon PERNOT, Dr

Role: CONTACT

s.pernot@bordeaux.unicancer.fr

+33556333347

Caroline LALET

Role: CONTACT

c.lalet@bordeaux.unicancer.fr

Other Identifiers

2024-A01797-40

Identifier Type: OTHER

Identifier Source: secondary_id

IB 2024-01

Identifier Type: -

Identifier Source: org_study_id